CellCentric exploring CCS1477 and p300/CBP inhibition for haematological cancers .September 5th 2017:CellCentric has signed an agreement with Laura Pasqualucci, Professor of Pathology and Cell Biology at Columbia University Medical School, New York USA, to explore the relevance of the company’s drug Candidate, CCS1477, in treating certain haematological cancers. This is in addition to existing collaborations with Professor Tim Somervaille, Consultant Haematologist and Senior Group Leader at the Cancer Research UK Manchester Institute and Professor Brian Huntly, Consultant Haematologist and Professor of Leukaemia Stem Cell Biology at the Cambridge Stem Cell Institute.
CellCentric at ASCO: further CCS1477 pre-clinical data. Johann de Bono to lead clinical evaluation.June 3rd 2017:CellCentric’s oral drug candidate CCS1477 targets p300/CBP for the treatment of castrate resistant prostate cancer (CRPC), the lethal form of the disease. Further biomarker and efficacy data is presented today supporting its application both as a monotherapy and in combination with other drugs such as Enzalutamide.
CellCentric is taking CCS1477 into the clinic in the UK and US, with Johann de Bono as the lead clinical Principal Investigator, a renowned world leader in the development of novel treatments for prostate cancer.